Patient characteristics at baseline
| Characteristic . | N = 119 . |
|---|---|
| Median age, y (range) | 57 (22–79) |
| Male sex, % | 56 |
| Median mo since first diagnosis of CML (range) | 71 (2–298) |
| Median WBC, × 109/L (range) | 12.7 (0.4–277) |
| Patients with WBC ≥ 50 × 109/L, % | 21 |
| Median blasts in peripheral blood, % (range) | 0.4 (0–33) |
| Patients with blasts ≥ 15%, % | 13 |
| Median basophils in peripheral blood, % (range) | 4 (0–62) |
| Patients with basophils ≥ 20%, % | 13 |
| Median platelet count, ×109/L (range) | 203 (4–3044) |
| Patients with platelets < 50 × 109/L, % | 21 |
| Median blasts in bone marrow at baseline, % (range) | 10.5 (0–28) |
| Patients with bone marrow blasts > 15%, % | 35 |
| Extramedullary involvement, % | 27 |
| Median duration of prior imatinib therapy, d (range) | 976 (2–2163) |
| Prior dose of imatinib therapy before entering the study, % | |
| ≥ 400 mg | 17.6 |
| ≥ 600 mg | 33.6 |
| ≥ 800 mg | 48.8 |
| Prior hematopoietic stem cell transplantation, % | 7.6 |
| Other chromosomal abnormalities, no. patients (%) | 35 (29) |
| Other prior therapies other than imatinib, % | 94 |
| Hydroxyurea | 92 |
| Interferon-α | 58 |
| Cytarabine | 26 |
| Patients with imatinib resistance, % | 81 |
| Patients with imatinib intolerance, % | 19 |
| Characteristic . | N = 119 . |
|---|---|
| Median age, y (range) | 57 (22–79) |
| Male sex, % | 56 |
| Median mo since first diagnosis of CML (range) | 71 (2–298) |
| Median WBC, × 109/L (range) | 12.7 (0.4–277) |
| Patients with WBC ≥ 50 × 109/L, % | 21 |
| Median blasts in peripheral blood, % (range) | 0.4 (0–33) |
| Patients with blasts ≥ 15%, % | 13 |
| Median basophils in peripheral blood, % (range) | 4 (0–62) |
| Patients with basophils ≥ 20%, % | 13 |
| Median platelet count, ×109/L (range) | 203 (4–3044) |
| Patients with platelets < 50 × 109/L, % | 21 |
| Median blasts in bone marrow at baseline, % (range) | 10.5 (0–28) |
| Patients with bone marrow blasts > 15%, % | 35 |
| Extramedullary involvement, % | 27 |
| Median duration of prior imatinib therapy, d (range) | 976 (2–2163) |
| Prior dose of imatinib therapy before entering the study, % | |
| ≥ 400 mg | 17.6 |
| ≥ 600 mg | 33.6 |
| ≥ 800 mg | 48.8 |
| Prior hematopoietic stem cell transplantation, % | 7.6 |
| Other chromosomal abnormalities, no. patients (%) | 35 (29) |
| Other prior therapies other than imatinib, % | 94 |
| Hydroxyurea | 92 |
| Interferon-α | 58 |
| Cytarabine | 26 |
| Patients with imatinib resistance, % | 81 |
| Patients with imatinib intolerance, % | 19 |
WBC indicates white blood cell.